Hong Kong-listed MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has received the CE mark for its AnchorMan left atrial appendage (LAA) occluder system and its guidance system, marking a significant milestone for the China-based medical device company. The approval paves the way for the commercialization of the device in Europe.
Product Overview
The AnchorMan LAA occluder system is the only approved semi-closed LAA occluder product in China. It is designed for percutaneous transcatheter closure of the left atrial appendage to prevent thromboembolism, a common complication in patients with atrial fibrillation. The system’s guidance component provides femoral vein and atrial septal access, enhancing procedural precision.
Regulatory and Market Significance
Both the AnchorMan occluder and guidance systems are already registered in China. The CE mark approval positions the device to address the growing demand for minimally invasive cardiac solutions in Europe, where LAA closure is a critical therapeutic area for stroke prevention.-Fineline Info & Tech
Leave a Reply